scholarly journals Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia

Blood ◽  
2011 ◽  
Vol 117 (4) ◽  
pp. 1390-1392 ◽  
Author(s):  
Julie Makani ◽  
Stephan Menzel ◽  
Siana Nkya ◽  
Sharon E. Cox ◽  
Emma Drasar ◽  
...  

Abstract Fetal hemoglobin (HbF, α2γ2) is a major contributor to the remarkable phenotypic heterogeneity of sickle cell anemia (SCA). Genetic variation at 3 principal loci (HBB cluster on chromosome 11p, HBS1L-MYB region on chromosome 6q, and BCL11A on chromosome 2p) have been shown to influence HbF levels and disease severity in β-thalassemia and SCA. Previous studies in SCA, however, have been restricted to populations from the African diaspora, which include multiple genealogies. We have investigated the influence of these 3 loci on HbF levels in sickle cell patients from Tanzania and in a small group of African British sickle patients. All 3 loci have a significant impact on the trait in both patient groups. The results suggest the presence of HBS1L-MYB variants affecting HbF in patients who are not tracked well by European-derived markers, such as rs9399137. Additional loci may be identified through independent genome-wide association studies in African populations.

Blood ◽  
2010 ◽  
Vol 115 (9) ◽  
pp. 1815-1822 ◽  
Author(s):  
Nadia Solovieff ◽  
Jacqueline N. Milton ◽  
Stephen W. Hartley ◽  
Richard Sherva ◽  
Paola Sebastiani ◽  
...  

Abstract In a genome-wide association study of 848 blacks with sickle cell anemia, we identified single nucleotide polymorphisms (SNPs) associated with fetal hemoglobin concentration. The most significant SNPs in a discovery sample were tested in a replication set of 305 blacks with sickle cell anemia and in subjects with hemoglobin E or β thalassemia trait from Thailand and Hong Kong. A novel region on chromosome 11 containing olfactory receptor genes OR51B5 and OR51B6 was identified by 6 SNPs (lowest P = 4.7E−08) and validated in the replication set. An additional olfactory receptor gene, OR51B2, was identified by a novel SNP set enrichment analysis. Genome-wide association studies also validated a previously identified SNP (rs766432) in BCL11A, a gene known to affect fetal hemoglobin levels (P = 2.6E−21) and in Thailand and Hong Kong subjects. Elements within the olfactory receptor gene cluster might play a regulatory role in γ-globin gene expression.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2471-2471 ◽  
Author(s):  
Nadia Timofeev ◽  
Paola Sebastiani ◽  
Steven H. Hartley ◽  
Clinton T. Baldwin ◽  
Martin H. Steinberg

Abstract Fetal hemoglobin (HbF) is the major genetic modulator of sickle cell anemia. Candidate gene-based and genome-wide association studies (GWAS) have provided strong evidence that single nucleotide polymorphisms (SNPs) linked to genes on chromosome 6q (HBS1L-MYB) and 2p (BCL11A), along with elements in cis to HBG help determine HbF concentration in untreated patients with sickle cell anemia and β thalassemia, and in normal individuals. The HbF response to hydroxyurea (HU) varies considerably among treated patients, even when compliance with treatment is good and patients are treated under controlled conditions. This suggests that genetic factors might affect the response to treatment with this agent. In the Multicenter Study of Hydroxyurea, 299 patients were randomized to receive either HU titrated to maximum tolerated doses, or a placebo, and HbF levels were measured before and at the completion of the randomized phase of the study. In 123 HU-treated patients, we completed GWAS using Illumina 370K chips that include approximately 350,000 haplotype tagging SNPs, and studied the association of SNPs with the change in HbF from baseline levels to levels measured at the end of the active treatment portion of the study. We conducted a GWAS using the analytical program PLINK, of approximately 273K SNPs with minor allele frequency >0.05, using linear regression and an additive model of inheritance. We selected for further investigation those SNPs with association that reached 0.05 significance, after we adjusted for sex. Because of the limited sample size that results in relatively large p-values, no single SNP reached so-called genome-wide significance after correcting for multiple comparisons using a Bonferroni correction (p-value <10-7) or 5% false discovery rate. Two SNPs had an association with p value <10–6 and 27 SNPs reached at least 10–5 significance. Noticeably, the SNP rs6899351 in FABP7 in 6q22.31 was associated with the largest increment in HbF after treatment with HU (6.9% change per copy of allele G, p-value 4 ×10–5). We also identified 2 SNPs in PDE7B (6q23.3) that were significantly associated with positive changes of HbF and 3 SNPs in MAP7 (6q23.3) that were significantly associated with a reduction of HbF after treatment. Using candidate gene association studies, we had previously shown that PDE7B and MAP7 were significantly associated with differential expression of HbF in sickle cell anemia. These new GWAS results suggest a regulatory role for these genes, or this region of chromosome 6q, in the HbF response to HU in sickle cell anemia. Analysis of the distribution of significant SNPs per chromosome also showed that chromosome 20 had a larger number of significant SNPs than expected at random, especially in CST9, one of a family of protease inhibitors. CST9 is tagged by 3 SNPs in the 370K array (rs2983639, rs2983640, rs10485646), 2 of which were associated with significant positive changes in HbF after treatment with HU and one with significant negative changes of HbF. Specifically, the average increase in HbF was 1.5% for each copy of allele G for SNP rs2983639 (p = 0.025), and 1.6% for each copy of allele A for SNP rs2983640 (p = 0.047), while the level of HbF decreased by approximately 1.5% for each copy of allele A for SNP rs10485646 (p = 0.035). The SNP rs2983640 is an exon variant that produces the amino acid change F-L. Although these SNPs do not individually reach genome-wide significance, cumulatively they provide strong evidence of association, as the probability that they are all simultaneously associated by chance is 10-4. Furthermore, we identified significant variants in other genes that belong to the same family of type 2 cysteine protease inhibitors, specifically 2 SNPs in CTS3 and 1 SNP in CTS5. Although the small sample size and the large number of SNPs tested suggest caution until these results are replicated in independent patient treatment groups, these preliminary findings suggest that type 2 cystatin genes and pseudogenes are associated with the HbF response to HU. If confirmed, it might be possible to use results like these to build a prognostic model of the HbF response to HU in sickle cell anemia.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1446-1446
Author(s):  
Paola Sebastiani ◽  
Nadia Timofeev ◽  
Steven H. Hartley ◽  
Daniel Dworkis ◽  
Lindsay Farrer ◽  
...  

Abstract Genome-wide association studies (GWAS) allow an assessment of associations between single nucleotide polymorphisms (SNPs) and phenotypes or traits of interest in a non-hypothesis driven manner. Previously, based on limited candidate gene association analysis, we showed that survival in sickle cell anemia and exceptional longevity (EL) in the general population share common genetic modifiers (Blood, 52a, 2007). This preliminary result suggested that aging mechanisms and associated genes might play a role in the variability of sickle cell anemia. Using GWAS, we now report strong evidence supporting this conjecture. We conducted a GWAS using an Illumina platform that permits genotyping up to 1 million haplotype-tagging SNPs spread across the genome, as well as other types of genetic variation, in large populations. We used the Illumina 610K SNP array to discover SNPs that are associated with different degrees of severity of sickle cell anemia in 684 patients. Patients were assigned to either a severe or mild disease category based on an integrated measure of sickle cell anemia severity that was determined by a network model that assigns a score predicting the risk of death (Blood110: 272, 2007). In parallel, we used the Illumina 370K SNP and the Illumina 1M SNP arrays to discover SNPs associated with EL in 877 centenarians enrolled in the New England Centenarian Study and 1,850 younger controls. In both studies, each SNP was tested for association with the traits of severe or less severe sickle cell anemia and EL using Bayesian tests of general, dominant and recessive associations (BMC Genet.9, 2008). We then identified those SNPs satisfying these 3 criteria: at least one model of association was 10 times more likely than no association in the GWAS of EL; the same model of association was at least 3 times more likely (because of the smaller sample size) than no association in the GWAS of sickle cell anemia severity, the same allele was more frequent in centenarians and in sickle cell anemia patients with milder disease. This analysis identified 140 SNPs in more than 50 genes and some intergenic regions that showed robust and consistent associations. This number is more than twice the number that would be expected by chance. Among the most ‘significant’ genes with associated SNPs were ARFGEF2, ADAMTS12, DOK5, DPP10, FGF21, KCNQ1, IRF4, MYO3B NAIF1, TNNI3K; more than one SNP was found in ARFGEF2, NAIF1, DPP10, SORCS3, TNNI3K. KCNQ1 has a putative role in blood circulation and regulation of heart contraction. The frequency of the common genotype for SNP rs108961 increases by almost 60% in sickle cell anemia patients with severe disease (27% versus 43%). The same common genotype in random Caucasian controls has frequency 34% that decreases to 29% in centenarians. Mutations in this gene are associated with long and short QT syndrome, with familial atrial fibrillation, heart disease and sudden death. SNPs in 2 of the genes (HAO2, a peroxisome protein involved in fatty acid oxidation, and MAP2K1, a MAP kinase involved in multiple biochemical signals) that were significantly associated with both sickle cell disease severity and EL in our earlier candidate gene studies, were also associated in the GWAS. GWAS also revealed significant association with CDKN2A, a cyclin-dependent kinase that has been associated with Type 2 diabetes, risk of myocardial infarction and triglyceride levels in several GWAS, and with FGF21, the fibroblast growth factor 21 precursor that has been shown to regulate glucose metabolism. CDKN2A has been associated with disease free survival in other studies. Common metabolic pathways are likely to influence the chance of developing complications of Mendelian and multigenic diseases and the likelihood of achieving EL. This might explain the commonality of genes whose SNPs are associated with the vascular complications of sickle cell anemia, arteriosclerosis and diabetes. A new paradigm suggests that hitherto unexpected genetic differences modulate a limited number of pathways that form a common route toward determining good health and disease.


2009 ◽  
Vol 9 ◽  
pp. 46-67 ◽  
Author(s):  
Martin H. Steinberg

The clinical course of patients with sickle cell anemia, a Mendelian trait, is characteristically highly variable. HbF concentration and the presence of a thalassemia are established modulators of the disease, but cannot account for all of its clinical heterogeneity. To find additional genetic modulators of disease, genotype-phenotype association studies, where single nucleotide polymorphisms (SNPs) in candidate genes are linked with a particular phenotype, have been informative. SNPs in several genes of the TGF-ß/MP superfamily, and some other genes linked to the endothelial function, and nitric oxide biology are associated with the subphenotypes of stroke, osteonecrosis, priapism, leg ulcers, pulmonary hypertension, and a more general measure of overall disease severity. Genome-wide association studies should help to confirm these observations and also to find hitherto unsuspected genetic modulators. Genetic association studies can have immediate prognostic value; they might also help to identify new pathophysiological pathways that could be susceptible to modulation.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3228-3228
Author(s):  
Jonathan Michael Flanagan ◽  
Heidi Linder ◽  
Vivien Sheehan ◽  
Thad A Howard ◽  
Banu Aygun ◽  
...  

Abstract Abstract 3228 Introduction: Stroke is one of the most catastrophic acute complications of sickle cell anemia (SCA), occurring in 11% of patients before 20 years of age. A further 20 to 30% of children with SCA will develop less clinically overt cerebrovascular disease events such as transient ischemic attacks (TIA) and silent infarcts. There is a definite need for biomarkers that could determine the cause of these irreversible cerebrovascular events and which might predict children at greatest risk. Previous studies of sibling pairs have shown that there is a genetic component to cerebrovascular disease development but few genetic modifiers have been validated as having a substantial effect on risk of stroke. The aim of this study was to perform an unbiased whole genome search for genetic modifiers of stroke risk in SCA. Methods: Pediatric patients with SCA and documented primary stroke (n=177) were compared to a pediatric control non-stroke group with SCA (n=335). All control patients were over 5 years old and without previous clinical stroke prior to beginning any clinical treatment. Genome wide association studies (GWAS) were performed using genotype data obtained from Affymetrix SNP6.0 arrays. A pooled DNA approach was used to perform whole exome sequencing (WES) by Illumina next generation sequencing of pooled control (n=104) and pooled stroke (n=120) groups. Results: From the Affymetrix SNP6.0 GWAS data, 139 single nucleotide polymorphisms (SNP) were identified with stroke association. From the WES, 294 non-synonymous mutations were found to be significantly associated with stroke. In combination, 11 mutations identified by WES were located within 250kb of a SNP identified by GWAS (Table 1). These 11 mutations represent key areas of the genome that are targets for further in depth study. To next validate the genetic variants identified by WES with association with risk of stroke, 21 candidate mutations were genotyped in an independent cohort of control (n=231) and stroke (n=57) patients with SCA. One mutation in GOLGB1 (Y1212C) was corroborated as having significant association with lower risk of stroke (p=0.02). Conclusion: This mutation in GOLGB1 is predicted to effect the golgi associated function of the encoded protein and future studies will focus on how this functional mutation may protect against development of cerebrovascular disease in the context of SCA. For all variants with significant association with stroke, the chromosomal position of each variant identified by WES (n=300, p<0.001) was compared to the location of all SNP markers (n=139, p<0.0001). We identified 11 variants by WES where there was at least one SNP marker within 250kb. These variants all represent excellent regions of the genome for future study. The four variants highlighted with a asterisk (*) are variants predicted by PolyPhen2 or SIFT to be deleterious. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3216-3216
Author(s):  
Jacqueline N Milton ◽  
Paola Sebastiani ◽  
Clinton T. Baldwin ◽  
Efthymia Melista ◽  
Victor R. Gordeuk ◽  
...  

Abstract Abstract 3216 Fetal hemoglobin (HbF) is the major genetic modifier of clinical course of sickle cell anemia (homozygosity for HBB glu6val). HbF level is also an important predictor of mortality. If it were possible to know at birth the HbF level likely to be present after stabilization of this measurement at about age 5 years, then an improved prognosis might be given and HbF-inducing treatments better informed. Levels of HbF in adults are highly heritable and the production of HbF is genetically regulated by several quantitative trait loci and by genetic elements linked to the HBB gene cluster. One of the most popular approaches to genetic risk prediction uses a summary of the risk alleles in the form of a genetic risk score (GRS) that is used as a covariate of the genetic prediction model. We present the development of a GRS for HbF in 841 patients from the Cooperative Study of Sickle Cell Disease (CSSCD) cohort patients and assessed its ability to predict HbF values in three independent cohorts that included PUSH (N=77), Walk-PHaSST (N=181), and C-Data from the Comprehensive Sickle Cell Centers program (N= 127). We used the results of a genome-wide association study (GWAS) of HbF in sickle cell anemia, in which patients were genotyped using the 610K Illumina array, and association of each of the ∼550K SNPs with HbF was tested using a linear regression model with gender adjusted additive genetic effects. To build the GRS, we sorted SNPs by increasing p-value, starting from the most significant SNP associated with HbF (rs766432, p-value=2.61×10−21), and pruned the list by removing SNPs in high LD (r2 > 0.8). We then used this list of SNPs to generate a sequence of nested GRS. We started with the GRS that included only the most significant SNP and generated the second GRS by adding the second SNP from the list of SNPs. The third GRS was generated by adding the 3rd SNP from the list of SNPs to the second GRS, and so on. We repeated this analysis including up to 10,000 SNPs (p-value< .02185) and hence generated 10,000 GRS, for each of the subjects in the CSSCD. Each of these GRS was included as covariate in a linear regression model and the regression coefficients of the resultant 10,000 linear regression models were estimated using Least Squares methods in the CSSCD data. The predictive value of these GRS models was then evaluated in three independent cohorts. In this evaluation, we computed the 10,000 GRS for each subjects in each data sets, and then used the 10,000 regression models estimated in the CSSCD data set to compute the expected HbF value of patients, given their GRS. We then assessed the predictive accuracy by computing the correlation between the observed and predicted values of HbF. To produce more stable predictions, we also created ensembles of predictive models. An ensemble of the first 14 GRS models including 14 SNPs had the best predictive value in all 3 data sets and explains 23.4% of the variability in HbF; the correlation between the predicted HbF and observed HbF was 0.44, 0.28 and 0.39 in the three different cohorts. Of these 14 SNPs, 6 were located in BCL11A; other SNPs were located in the olfactory receptor region and the in chromosome 11p15 and the site of the HBB gene cluster and were found previously to be associated with HbF. We next compared these results to predictive models in which we included gender, coincident alpha thalassemia, and HBB haplotypes for prediction. The model including gender and alpha thalassemia explained only 2.6% of the variability of HbF in the discovery cohort and the model including HBB haplotypes explained 2.35% of the variability of HbF in the discovery cohort and neither model showed a significant correlation between the predicted and observed HbF in the three other cohorts. In addition, combining the non-genetic information with the GRS did not help to explain more of the variability in HbF. With as few as 14 SNPs we can explain more of the variability in HbF and do a better job of prediction in comparison to using other non-genetic risk factors or genome-wide significant SNPs; however, we still cannot explain all of the variability in HbF that is due to heritability. These results suggest that knowing the genotype of a few SNPs can help to predict HbF that after they have stabilized. Prediction of HbF at an early age has the potential to help foretell some features of the severity of the clinical course of the disease and aid to optimize the clinical management of patients. Disclosures: No relevant conflicts of interest to declare.


PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e111464 ◽  
Author(s):  
Siana Nkya Mtatiro ◽  
Tarjinder Singh ◽  
Helen Rooks ◽  
Josephine Mgaya ◽  
Harvest Mariki ◽  
...  

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 33-34
Author(s):  
Anu Marahatta ◽  
Thad A. Howard ◽  
Susan E. Stuber ◽  
Kathryn L McElhinney ◽  
Leon Tshilolo ◽  
...  

Introduction: Elevated levels of fetal hemoglobin (HbF) are known to ameliorate both the morbidity and mortality of sickle cell anemia (SCA). Sustained post-natal HbF expression is heritable and regulated by multiple quantitative trait loci. Previous genomic studies have identified three major gene loci (BCL11A, HBS1L-MYB, and HBG2) that account for ~40% of HbF variation in SCA, but additional genetic modifiers remain to be discovered. We performed a genome wide association study (GWAS) using DNA collected from multiple cohorts of children with SCA, to identify novel genes and variants involved in HbF expression. Methods: We analyzed genomic DNA from 1009 children with SCA and pre-treatment steady-state HbF levels who enrolled in prospective research trials from the United States (HUSTLE, SWiTCH, TWiTCH), the Caribbean (SACRED) or sub-Saharan Africa (REACH, NOHARM). Whole blood DNA was first genotyped using the H3Africa SNP array (Illumina) that identifies over 2.2 million single nucleotide variants (SNVs) across the genome. Most samples also underwent whole exome sequencing (WES) using NimbleGen VCRome 2.1 capture reagents and the Illumina HiSeq2500 platform analysis, which identifies coding variants in all known exons. Square root transformed HbF values were the continuous variable for association testing using single-locus mixed model (EMMAX) adjusted for population stratification, with both age and sex as co-variates. The GWAS approach included 3 distinct steps. First, we performed two independent GWAS discovery steps using distinct African populations; these were designated Discovery I (N=211) and Discovery II (223). Second, only SNVs that were significant (p&lt;0.05) in both datasets were then selected for two independent replication steps; these were designated either African-American (N=157) or African (N=269). Third, the SNVs that were significant in both dual discovery and at least one of the replication cohorts were then verified using an additional Caribbean cohort (N=149) with TaqMan techniques for genotyping specific variants. Through this multistep process, we searched for genomic loci with consistent HbF associations across multiple cohorts. Results: From the combined SNP and WES dataset, 8 BCL11A variants passed genome wide significance (p&lt;10-8) in the discovery analysis, and 1,048 additional variants were identified with nominal HbF association (p&lt;0.001). We found that 173 of these novel variants had sustained association in at least one of the replication cohorts (p&lt;0.05). We selected 20 variants with the strongest and most consistent associations with HbF from the discovery and replication analyses for further verification (Table 1). Expected HbF associations with BCL11A (rs1427407) and HBS1L-MYB (rs4895441) were identified. Among other 18 novel candidate variants, the rs77737207 variant (allele frequency ~0.10) near the RUNX1T1 locus was strongly associated with lower HbF levels, while coding variant rs2279587 (allele frequency ~0.03) in the ITGA1 gene approached statistical significance (p&lt;0.08) in the final verification cohort and was associated with higher levels of HbF. Conclusions: Our large GWAS of HbF with diverse global cohorts of children with SCA from Africa, the United States, and the Caribbean validated the strong associations of HbF with common genetic variants near the BCL11A and HBS1L-MYB gene loci. We also identified two novel gene loci, ITGA1 and RUNX1T1, that have statistical associations with HbF expression. The RUNX1T1 gene is a broad transcriptional corepressor known to impact myeloid differentiation in hematopoiesis, while ITGA1 encodes the integrin alpha subunit of a cell-surface receptor involved in cell-cell adhesion and inflammation. Both of these genes represent novel loci that may be involved in the regulation of HbF expression in children with SCA and should be investigated further using cellular and animal models. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3388-3388
Author(s):  
Vinod Vathipadiekal ◽  
Abdulrahman Alsultan ◽  
John Farrell ◽  
A.M Al-Rubaish ◽  
Fahad Al-Muhanna ◽  
...  

Abstract Fetal hemoglobin (HbF) inhibits HbS polymerization. Because of this, sufficient HbF in most sickle erythrocytes can lead to a milder disease phenotype. HbF levels differ amongst the β-globin gene (HBB) cluster haplotypes of sickle cell anemia. In the Arab-Indian (AI) haplotype, HbF was about 20% compared with 5-10% in the Bantu, Benin, and Senegal haplotypes. Functional elements linked to the HBB haplotype are likely to regulate the expression of HbF in addition to the effects of trans-acting modulators. To identify cis-acting SNPs in the HBB gene cluster that differentiate the AI haplotype from all others, including the Senegal haplotype-the Senegal haplotype shares some SNPs with the AI haplotype but its carriers have lower HbF-we studied patients with sickle cell anemia who were homozygous for HBB haplotypes by genome-wide SNP association analysis (GWAS; Table). First, we compared the results of GWAS of 42 Saudi AI haplotype homozygotes with GWAS in 71 Saudi Benin haplotype homozygotes. The only variants distinguishing these 2 populations with genome-wide significance (p-values between 9.6E-07 and 2.7E-45) were 223 SNPs in chromosome 11p15 from positions 3.5 to 6.5 mb. This region included the HBB gene cluster, its locus control region (LCR) and the upstream and downstream olfactory receptor gene clusters. The minor allele frequency of SNPs in MYB (chr 6q23), BCL11A (chr 2p16) and KLF1 (chr 19), trans-acting loci that affect expression of the HbF genes, were similar in these 2 cohorts. A novel candidate trans-acting locus was not found, however our power to detect such an association was low. We followed-up these observations by comparing allele frequencies in 303 African American cases homozygous for the haplotypes shown in the Table. Thirteen GWAS-significant SNPs, in addition to rs7482144 and rs10128556, were present in all AI haplotype cases but not in 83 Senegal haplotype chromosomes. The allele frequency of these SNPs was replicated in 62 independent AI haplotype cases. Rs2472530 is in the coding region of OR52A5; rs16912979, rs4910743 and rs4601817 are in the HBB gene cluster LCR; rs16912979 in DNase I hypersensitive site-4 altered motifs for POLR2A, GATA1, and GATA2 binding.The minor allele of rs10837771 causes a missense mutation in OR51B4 an upstream olfactory receptor gene. To see if any of these or other alleles might sometimes be associated with HbF in the Bantu and Benin haplotyes, we selected homozygotes and compound heterozygous for these haplotypes who had unexplained and uncharacteristically high HbF. Thirty-one African Americans, aged ≥5 yrs. who had a HbF of 21% were compared with 350 similar cases who had a mean HbF of 3%. Four additional SNPs on chromosome 11, from positions ranging from 5536415 to 5543705 in the UBQLNL/HBG2, region and present in 45-48% of AI haplotype and 3-13% of other haplotypes, were found at higher frequencies in the high HbF group compared with the low HbF group. These SNPs also altered transcription factor binding motifs. Loci marked by SNPs that distinguish the AI from the Senegal and other HBB haplotypes might contain functionally important polymorphisms and account in part for high HbF in AI haplotype sickle cell anemia, independent of, or in addition to, the effects associated with rs7482144 or rs10128556. They might also be rarely associated with high HbF found in other haplotypes. These observations provide a foundation for mechanistic studies focused on the role of these variants in the expression of their linked HbF genes.Table 1.non-codedallelegenomic locationSaudi AI(n=42)Saudi ben.ben(n=71)AA ben.ben(n=264)AA ban.ban(n=31)AA sen.sen(n=8)HbF (%)1711669rs10837771Gexon OR51B410.020.0200rs4601817GLCR10.020.0400rs4910743CLCR10.010.0100rs16912979CLCR00.960.920.111rs10488675Gintron HBE110.01000rs7482144*AHBG210001rs10128556#TIntron HBBP110001rs7935470COR51V110.020.0300rs10837582GOR51V1100.0200rs11036227TOR51V110000rs10734485COR51A1P00.990.9711rs10837461AOR52A110.01000rs2472522GOR52A110.01000rs2472530Gexon OR52A510.01000rs2499948TOR52A510.020.010.020Allele frequencies in haplotypes of sickle cell anemia. * Xmn1 5' HBG 2 restriction site. This SNP, not present on the SNP microarray, was genotyped independently; # LD with rs7482144; AA designates African Americans; ben-Benin; ban-Bantu; sen-Senegal. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 150-150
Author(s):  
Paola Sebastiani ◽  
Ling Wang ◽  
Thomas Perls ◽  
Dellara F. Terry ◽  
Monty Montano ◽  
...  

Abstract Phenotypic heterogeneity is a well known characteristic of sickle cell anemia. Patients have different rates of hemolysis-related complications, like pulmonary hypertension, priapism and leg ulceration, and viscosity/vasoocclusion-related complications, like painful episodes, acute chest syndrome and osteonecrosis; they also have variation in levels of HbF and hematocrit. To integrate individual disease variables into a global measure of severity, we developed a Bayesian network model that described the complex associations of 25 clinical and laboratory variables, deriving a score that we used to define disease severity (0, least severe to 1, most severe) as the risk of death within 5 years (Sebastiani et al, Blood 2007). This initial network, validated in 2 unrelated patient populations, did not incorporate the genetic heterogeneity that is likely to modulate its components. Accordingly, we studied the association of single nucleotide polymorphisms (964 SNPs) in candidate genes (315 genes) using a Bayesian beta regression model of the severity score in 741 HBB glu6val homozygotes, aged more than 18 years. Forty-three SNPs in about 25 genes were associated with disease severity. Some associated SNPs tag genes that affect nitric oxide and oxidative biology and the endothelium, such as NOS1, ASS, KL, HMOX1, ECE1, KDR, FLT1. Homozygosity for an intronic SNP in ECE1 is associated with a increase of severity (OR=3.5). As expected, some associations were consistent with our previous findings. For example, the same SNP in ECE1 and TGFBR3, that was highly predictive of severity, was also strongly associated with sickle cell stroke (Sebastiani et al, Nature Genet 2005). Also, the association with severity of genes in the TGF-beta signaling pathway, including BMP6 and TGFBR3, were also associated with individual disease complications. Other associated genes play a less obvious role in the pathobiology of disease, e.g., HAO2, but are very strongly associated with the phenotype of severity (probability of a chance association, for HAO2, 10−6). Several of the genes associated with severity, including KL, PRKCA, FLT1 and MET have been related to aging, as suggested by gene expression profiling and studies in model organisms for aging. In genome-wide studies of the genetic basis of exceptional longevity, we found associations with some of the same genes that were associated with severity in sickle cell anemia. Perhaps increased oxidative stress, and the relentless progression of vasculopathy in sickle cell anemia, cause accelerated tissue damage that is modulated by a set of genes similar to those involved in the normal aging process. We suggest that the disease severity score can be used as a phenotype integrating many features of the disease, for genetic association studies. As we add the results of unbiased genome-wide association studies to capture polymorphisms not included in candidate gene studies, we can develop a predictive network with even greater reliability than one using only clinical and laboratory variables. Such networks might also identify pathways that could be targeted to alter the course of disease.


Sign in / Sign up

Export Citation Format

Share Document